Sinopharm Group (SEHK:1099) Q1 Net Margin Of 1.6% Tests Thin Profit Narrative

Simply Wall St.04-23

Sinopharm Group (SEHK:1099) opened 2026 with Q1 revenue of about CNY 17.8b and basic EPS of CNY 0.52, setting the tone against a trailing twelve month profile that shows revenue of roughly CNY 574.7b ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629839475?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496","is_english":true,"pubTime":"2026-04-23 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629839475","market":"us","top_or_hot":-1,"title":"Sinopharm Group (SEHK:1099) Q1 Net Margin Of 1.6% Tests Thin Profit Narrative","media":"Simply Wall St.","content":"<div>\n<p>Sinopharm Group (SEHK:1099) opened 2026 with Q1 revenue of about CNY 17.8b and basic EPS of CNY 0.52, setting the tone against a trailing twelve month profile that shows revenue of roughly CNY 574.7b ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-sehk1099-q1-net-margin-of-16-tests-thin-prof\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Group (SEHK:1099) Q1 Net Margin Of 1.6% Tests Thin Profit Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Group (SEHK:1099) Q1 Net Margin Of 1.6% Tests Thin Profit Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-23 19:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-sehk1099-q1-net-margin-of-16-tests-thin-prof><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sinopharm Group (SEHK:1099) opened 2026 with Q1 revenue of about CNY 17.8b and basic EPS of CNY 0.52, setting the tone against a trailing twelve month profile that shows revenue of roughly CNY 574.7b ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-sehk1099-q1-net-margin-of-16-tests-thin-prof\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-sehk1099-q1-net-margin-of-16-tests-thin-prof","article_id":"2629839475","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/sinopharm-group-sehk1099-q1-net-margin-of-16-tests-thin-prof","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629839475","pubTimestamp":1776942740,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sinopharm Group (SEHK:1099) opened 2026 with Q1 revenue of about CNY 17.8b and basic EPS of CNY 0.52, setting the tone against a trailing twelve month profile that shows revenue of roughly CNY 574.7b and EPS of CNY 2.28. Over recent quarters investors have seen quarterly revenue move from about CNY 141.7b in Q1 2025 to CNY 145.4b in Q3 2025 and CNY 143.7b in Q4 2025, with basic EPS ranging from CNY 0.47 to CNY 3.29 across that period as the business cycled through different earnings levels...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","01099":"国药控股","BK1500":"做空集合股","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK1197":"保健护理产品经销商"},"translate_title":"国药集团（SEHK：1099）第一季度净利润1.6%考验利润微薄叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01099":0.9},"content_text":"Sinopharm Group (SEHK:1099) opened 2026 with Q1 revenue of about CNY 17.8b and basic EPS of CNY 0.52, setting the tone against a trailing twelve month profile that shows revenue of roughly CNY 574.7b and EPS of CNY 2.28. Over recent quarters investors have seen quarterly revenue move from about CNY 141.7b in Q1 2025 to CNY 145.4b in Q3 2025 and CNY 143.7b in Q4 2025, with basic EPS ranging from CNY 0.47 to CNY 3.29 across that period as the business cycled through different earnings levels. With a reported net profit margin of 1.2% and modest earnings growth over the last year, the focus now shifts to how durable those margins look as the latest results are digested. See our full analysis for Sinopharm Group. The next step is setting these numbers against the widely followed market stories around Sinopharm Group to see which narratives hold up under the latest margin and earnings profile and which start to look out of date. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:1099 Revenue & Expenses Breakdown as at Apr 2026 AdvertisementTTM profit at CNY 7.1b on 1.2% margin  On a trailing basis, Sinopharm Group generated about CNY 7.1b in net income on CNY 574.7b of revenue, which works out to a 1.2% net profit margin for the last 12 months. What stands out for a more bullish take is that modest 0.4% earnings growth over the last year sits alongside this 1.2% margin, which\n     matches the margin level cited for the prior year and suggests recent profit levels have been relatively steady at a low single digit, rather than swinging sharply with revenue of over CNY 570b, and provides some backing for investors who see a large, system critical distributor with consistent, if thin, profitability as a core healthcare holding.    Revenue growth runs at 5.2% per year  Revenue growth is reported at 5.2% per year over the recent period, with trailing 12 month revenue at about CNY 574.7b compared with earlier levels such as CNY 584.5b in the dataset. Critics taking a more bearish stance often focus on a five year average EPS decline of 1.7% per year against this 5.2% revenue growth, and that tension shows up here as\n     earnings over the last 12 months rising only 0.4% even as revenue trends higher, which points to limited flow through from top line to bottom line, and a Q1 2026 net income figure of CNY 287.5m on CNY 17.8b of revenue, which illustrates how a distribution heavy model can keep margins low even when sales are large.    To see how investors weigh this revenue growth against earnings and valuation, you can tap into the wider community view through the 📊 Read the what the Community is saying about Sinopharm Group.. Low 7.5x P/E and DCF fair value gap  The shares trade on a P/E of 7.5x compared with a Hong Kong healthcare industry average of 15.4x and a peer average of 23.9x, while the current price of HK$19.56 sits well below a stated DCF fair value of HK$69.80. Supporters of a more bullish narrative point to this large gap between HK$19.56 and the DCF fair value of HK$69.80, and the data here\n     shows that this valuation sits alongside modest trailing earnings growth and a stable 1.2% margin, which value oriented investors may view as underappreciated, and highlights that the low P/E multiple is being applied to a business with CNY 7.1b in trailing net income and CNY 574.7b in revenue, rather than a company with shrinking sales or losses.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Sinopharm Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. If this mix of low margin stability, valuation gap, and mixed earnings signals leaves you undecided, act now to assess the trade off yourself by checking the 4 key rewards and 1 important warning sign. See What Else Is Out There Thin 1.2% margins, limited earnings growth against 5.2% revenue growth, and a five year average EPS decline of 1.7% point to weak profit conversion. If that tight margin profile makes you want businesses where more revenue reaches the bottom line, compare this against 237 high quality undervalued stocks to see if other ideas look stronger today.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629839475","isCrawlerRequest":true}